Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (AKBA) has granted stock options to seven newly-hired employees as part of their employment inducement package. The options allow for the purchase of a total of 130,763 shares of Akebia's common stock at an exercise price of $2.24 per share, matching the closing price on January 31, 2025.
The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and falls under Akebia's inducement award program, complying with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (AKBA) ha concesso opzioni su azioni a sette nuovi dipendenti come parte del loro pacchetto di incentivazione all'assunzione. Le opzioni consentono l'acquisto di un totale di 130.763 azioni comuni di Akebia a un prezzo di esercizio di 2,24 $ per azione, corrispondente al prezzo di chiusura del 31 gennaio 2025.
Le opzioni prevedono un programma di vesting di quattro anni, con il 25%che diventa disponibile dopo il primo anno e il restante 75% che matura trimestralmente successivamente, subordinato alla continuazione del rapporto di lavoro. Ogni opzione ha un termine di 10 anni e rientra nel programma di premi di incentivazione di Akebia, in conformità con la Regola di quotazione Nasdaq 5635(c)(4).
Akebia Therapeutics (AKBA) ha otorgado opciones sobre acciones a siete nuevos empleados como parte de su paquete de incentivos por contratación. Las opciones permiten la compra de un total de 130,763 acciones ordinarias de Akebia a un precio de ejercicio de $2.24 por acción, igualando el precio de cierre del 31 de enero de 2025.
Las opciones tienen un cronograma de adquisición de cuatro años, con un 25% que se adquiere después del primer año y el 75% restante que se adquiere trimestralmente a partir de entonces, dependiendo de la continuidad del empleo. Cada opción tiene un plazo de 10 años y se enmarca dentro del programa de premios de incentivos de Akebia, cumpliendo con la Regla de Listado de Nasdaq 5635(c)(4).
Akebia Therapeutics (AKBA)는 신규 채용된 직원 7명에게 고용 유도 패키지의 일환으로 주식 옵션을 부여했습니다. 이 옵션은 130,763주의 Akebia 보통주를 주당 $2.24의 행사 가격으로 구매할 수 있으며, 이는 2025년 1월 31일 종가와 일치합니다.
이 옵션은 4년의 베스팅 일정이 있으며, 첫해가 지나면 25%가 베스트되고 나머지 75%는 이후 분기별로 베스트됩니다. 이는 계속 고용되는 것을 조건으로 합니다. 각 옵션은 10년 기간을 가지며, Akebia의 유도 상여 프로그램에 해당하며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Akebia Therapeutics (AKBA) a accordé des options d'achat d'actions à sept nouveaux employés dans le cadre de leur package d'incitation à l'emploi. Les options permettent l'achat d'un total de 130 763 actions ordinaires d'Akebia à un prix d'exercice de 2,24 $ par action, correspondant au prix de clôture du 31 janvier 2025.
Les options disposent d'un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition après la première année et les 75 % restants s'acquérant trimestriellement par la suite, sous réserve de la continuité de l'emploi. Chaque option a une duree de 10 ans et fait partie du programme d'attribution d'incitation d'Akebia, en conformité avec la règle d'inscription Nasdaq 5635(c)(4).
Akebia Therapeutics (AKBA) hat sieben neu eingestellten Mitarbeitern Aktienoptionen als Teil ihres Beschäftigungspakets gewährt. Die Optionen ermöglichen den Kauf von insgesamt 130.763 Aktien von Akebia zu einem Ausübungspreis von 2,24 $ pro Aktie, was dem Schlusskurs am 31. Januar 2025 entspricht.
Die Optionen haben einen Vested-Zeitplan von vier Jahren, wobei 25% nach dem ersten Jahr und die verbleibenden 75% anschließend vierteljährlich fällig werden, abhängig von der weiteren Beschäftigung. Jede Option hat eine Laufzeit von 10 Jahren und fällt unter das Incentive-Programm von Akebia, das den Nasdaq-Listing-Regeln 5635(c)(4) entspricht.
- None.
- None.
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 130,763 shares of Akebia’s common stock on January 31, 2025. The options were granted as an inducement material to teach employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
How many shares were included in Akebia Therapeutics' (AKBA) January 2025 inducement grants?
What is the exercise price for AKBA's January 2025 inducement stock options?
What is the vesting schedule for AKBA's January 2025 inducement stock options?
How long is the term of AKBA's January 2025 inducement stock options?
